ÂÜÀòÂÒÂ×

Jay joined Abingworth’s Menlo Park office in August 2021, bringing more than 15 years of experience in investment, consulting, and academic research in the life sciences industry.

Previously, Jay was a Director at AbbVie Ventures, the corporate venture capital arm of AbbVie, focusing on early-stage biotech investments. He played an instrumental role in their investments in Accent Therapeutics and Caribou Biosciences (NASDAQ: CRBU) and supported portfolio companies including Disarm Therapeutics (acquired by Lilly) and Jnana Therapeutics. Jay was also responsible for sourcing multiple seed-stage opportunities and formulating theses in key investment areas. Before AbbVie, Jay worked as a management consultant at ZS Associates and as the leader of an NIH-funded drug discovery research lab in Chicago.